Brad Poore

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10518351/publications.pdf

Version: 2024-02-01

16 papers	800 citations	1162889 8 h-index	1281743 11 g-index
16 all docs	16 docs citations	16 times ranked	2010 citing authors

#	Article	IF	Citations
1	Retrospective Evaluation of the Antibody Prevalence in Epilepsy and Encephalopathy (APE2) Score. journal of applied laboratory medicine, The, 2022, 7, 36-45.	0.6	0
2	FSMP-18. COMPREHENSIVE METABOLIC PROFILING OF HIGH MYC MEDULLOBLASTOMA REVEALS KEY DIFFERENCES BETWEEN IN VITRO AND IN VIVO GLUCOSE AND GLUTAMINE USAGE. Neuro-Oncology Advances, 2021, 3, i19-i19.	0.4	0
3	TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. Cancer Letters, 2021, 504, 137-145.	3.2	5
4	OTME-9. Comprehensive Metabolic Profiling Of high MYC Medulloblastoma Reveals Key Differences Between In Vitro And In Vivo Glucose And Glutamine Usage. Neuro-Oncology Advances, 2021, 3, ii15-ii15.	0.4	1
5	Gamma Glutamyl Transferase Activity Has Limited Utility in Assessment of Alkaline Phosphatase Elevations. journal of applied laboratory medicine, The, 2021, 6, 1623-1627.	0.6	1
6	Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma. Cancers, 2020, 12, 643.	1.7	13
7	CSIG-21. BAF60C/SMARCD3 REGULATES TUMOR CELL DISSEMINATION IN MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, ii32-ii32.	0.6	0
8	Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. Clinical Cancer Research, 2019, 25, 5925-5936.	3.2	22
9	ATRT-04. UNBIASED METABOLIC PROFILING OF ATYPICAL TERATOID/RHABDOID TUMORS PREDICTS SENSITIVITY TO GLUTAMINE METABOLIC INHIBITORS. Neuro-Oncology, 2019, 21, ii63-ii63.	0.6	0
10	Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin. Neuro-Oncology, 2019, 21, 252-263.	0.6	21
11	MBRS-61. IN VIVO METABOLOMICS REVEALS A POTENT COMBINATION THERAPY FOR MYC-DRIVEN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i141-i141.	0.6	0
12	Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5328-36.	3.3	180
13	Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold. ACS Medicinal Chemistry Letters, 2016, 7, 520-524.	1.3	50
14	Dysregulated metabolism contributes to oncogenesis. Seminars in Cancer Biology, 2015, 35, S129-S150.	4.3	225
15	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
16	Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. Nature Communications, 2014, 5, 5369.	5.8	62